Asthma Clinical Trial
Official title:
Effect of Azithromycin With ICS/LABA in Non-eosinophilic Chest Tightness Variant Asthma: a Multicentre Randomized Trial
Bronchial asthma (abbr. asthma) is one of common airway chronic inflammatory disease which usually threatens human health. Typical symptoms of asthma are recurrent wheezing, shortness of breath, chest tightness and cough, usually happened at night or in early morning. However, there are still some patients who persist only clinical manifestations of chest tightness, namely, chest tightness variant asthma (CTVA). This subgroup of asthma usually lacks asthma-specific clinical features, therefore, often misdiagnosed and lack of effective treatment for a long time. The investigators' previous studies have found that CTVA has eosinophilic and non-eosinophilic subtypes. These patients with non-eosinophilic CTVA (NE-CTVA) are not sensitive to ICS/LABA, which guidelines recommend. At present, the specific treatment plan for NE-CTVA is urgently needed to elucidate. Azithromycin has immunomodulatory and anti-inflammatory effects in addition to their antibacterial effects. Maintenance treatment with azithromycin has been proved to be effective in chronic neutrophilic airway diseases and severe asthma. However, there are no clinical studies to confirm the effectiveness of azithromycin in non-eosinophilic asthma, especially atypical asthma such as NE-CTVA. Now the investigators performed a national multi-center study to explore whether azithromycin improves asthma symptom control and improves quality of life in people with NE-CTVA. Finally, to find an optimal treatment for NE-CTVA.
Status | Not yet recruiting |
Enrollment | 248 |
Est. completion date | March 31, 2024 |
Est. primary completion date | March 31, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 14 Years to 80 Years |
Eligibility | Inclusion Criteria: 1. all subjects agreed to participate, understand the project, observe the use of drugs, agree to follow-up, and signed informed consent; 2. the age of more than 14 and less 80 years old, gender and ethnicity are not limited; 3. the duration time was more than 6 months,and chest tightness was the only complaint, without breathing, short of breath, chronic cough; 4. no wheezing; 5. a diagnosis of asthma supported by one or more other characteristics: - bronchial provocation test positive; - improvement in forced expiratory volume at one second (FEV1) of more than 12% and 200 ml after inhaled salbutamol; - variability in diurnal peak expiratory flow (PEF) of more than 10% for one day during one week. 6. blood eosinophils < 150/µl and FeNO < 20 ppb; 7. exclude the following diseases by the corresponding doctors: coronary heart disease, myocarditis, heart failure, GERD, neuromuscular disease, and mental disease. Exclusion Criteria: 1. can not cooperate with related inspection or for other reasons; 2. patients with chronic obstructive pulmonary disease, interstitial pneumonia, active tuberculosis, community acquired pneumonia, lung cancer, bronchiectasis, cor pulmonale, pulmonary embolism, and accompanied with serious systematic disease (such as coronary heart disease, myocarditis, heart failure, gastroesophageal reflux disease, neuromuscular disease, etc); 3. history of chronic hepatic kidney or neurologic disorder; 4. history of drug abuse, alcohol abuse or anesthesia or with a history of mental illness (schizophrenia, obsessive-compulsive disorder, depression) and against personality, motivation, suspicious, or other emotional or mental issues that may affect participation in the study; 5. taking part in other drug clinical trial project, or drop out less than 3 months; 6. during pregnancy, lactation women; 7. obvious abnormal of High Resolution CT; 8. macrolide allergy; 9. received azithromycin treatment in the past 2 weeks; 10. hearing impairment or abnormally prolonged QTc interval. |
Country | Name | City | State |
---|---|---|---|
China | China-Japan Friendship Hospital | Beijing | Beijing |
China | The Second Xiangya Hospital of Central South University | Changsha | Hunan |
China | Xinqiao Hospital, Third Military Medical University | Chongqing | Chongqing |
China | The First Affiliated Hospital,Guangzhou Medical University | Guangzhou | Guangdong |
China | The Second Affiliated Hospital, School of Medicine, Zhejiang University, China | Hanzhou | Zhejiang |
China | Qilu Hospital, Shandong University | Jinan | Shandong |
China | Jiangsu Province Hospital | Nanjing | Jiangsu |
China | Changhai Hospital, Second Military Medical University | Shanghai | Shanghai |
China | Ruijin Hospital, Shanghai Jiaotong University | Shanghai | Shanghai |
China | Shanghai General Hospital | Shanghai | Shanghai |
China | Zhongshan Hospital, Fudan University | Shanghai | Shanghai |
China | The Central Hospital of Shenyang Military | Shenyang | Liaoning |
China | Xijing Hospital | Xi'an | Shaanxi |
Lead Sponsor | Collaborator |
---|---|
Second Affiliated Hospital, School of Medicine, Zhejiang University |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | r-ACQ | Revised-asthma control questionnaire. | Change from Baseline ACQ at 12 weeks | |
Secondary | FEV1 | Perform pulmonary function tests of patients and record the forced expiratory volume in one second. | Change from Baseline at 4 weeks, 8 weeks, and 12 weeks | |
Secondary | Airway responsiveness | Perform pulmonary function tests of patients and record the PD20-FEV1. | Change from Baseline at 4 weeks, 8 weeks, and 12 weeks | |
Secondary | PEF | Perform pulmonary function tests of patients and record the peak expiratory flow. | Change from Baseline at 4 weeks, 8 weeks, and 12 weeks | |
Secondary | AQLQ | Asthma quality of life questionnaire. | Change from Baseline at 4 weeks, 8 weeks, and 12 weeks | |
Secondary | SAS | Self-rating Anxiety Scale. | Change from Baseline at 4 weeks, 8 weeks, and 12 weeks | |
Secondary | SDS | Self-rating Depression Scale. | Change from Baseline at 4 weeks, 8 weeks, and 12 weeks | |
Secondary | Numbers of emergency or hospitalization | Record the numbers of emergency or hospitalization because asthma. | Change from Baseline at 4 weeks, 8 weeks, and 12 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT04410523 -
Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma
|
Phase 2 | |
Completed |
NCT04624425 -
Additional Effects of Segmental Breathing In Asthma
|
N/A | |
Active, not recruiting |
NCT03927820 -
A Pharmacist-Led Intervention to Increase Inhaler Access and Reduce Hospital Readmissions (PILLAR)
|
N/A | |
Completed |
NCT04617015 -
Defining and Treating Depression-related Asthma
|
Early Phase 1 | |
Recruiting |
NCT03694158 -
Investigating Dupilumab's Effect in Asthma by Genotype
|
Phase 4 | |
Terminated |
NCT04946318 -
Study of Safety of CSJ117 in Participants With Moderate to Severe Uncontrolled Asthma
|
Phase 2 | |
Completed |
NCT04450108 -
Vivatmo Pro™ for Fractional Exhaled Nitric Oxide (FeNO) Monitoring in U.S. Asthmatic Patients
|
N/A | |
Completed |
NCT03086460 -
A Dose Ranging Study With CHF 1531 in Subjects With Asthma (FLASH)
|
Phase 2 | |
Completed |
NCT01160224 -
Oral GW766944 (Oral CCR3 Antagonist)
|
Phase 2 | |
Completed |
NCT03186209 -
Efficacy and Safety Study of Benralizumab in Patients With Uncontrolled Asthma on Medium to High Dose Inhaled Corticosteroid Plus LABA (MIRACLE)
|
Phase 3 | |
Completed |
NCT02502734 -
Effect of Inhaled Fluticasone Furoate on Short-term Growth in Paediatric Subjects With Asthma
|
Phase 3 | |
Completed |
NCT01715844 -
L-Citrulline Supplementation Pilot Study for Overweight Late Onset Asthmatics
|
Phase 1 | |
Terminated |
NCT04993443 -
First-In-Human Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of LQ036
|
Phase 1 | |
Completed |
NCT02787863 -
Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology
|
Phase 4 | |
Recruiting |
NCT06033833 -
Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study
|
Phase 2 | |
Completed |
NCT03257995 -
Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts in Adult Subjects With Asthma.
|
Phase 2 | |
Completed |
NCT02212483 -
Clinical Effectiveness and Economical Impact of Medical Indoor Environment Counselors Visiting Homes of Asthma Patients
|
N/A | |
Recruiting |
NCT04872309 -
MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology
|
||
Withdrawn |
NCT01468805 -
Childhood Asthma Reduction Study
|
N/A | |
Recruiting |
NCT05145894 -
Differentiation of Asthma/COPD Exacerbation and Stable State Using Automated Lung Sound Analysis With LungPass Device
|